Alessandra Bulotta

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial

Vanesa Gregorc, Silvia Novello, Chiara Lazzari et al. · The Lancet Oncology · 2014 · 158 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

Pierfrancesco Tassone, Maria Teresa Di Martino, Monica Ventura et al. · Cancer Biology & Therapy · 2009 · 91 citations · Full text

Medicine, Molecular Biology, Oncology +17

In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer

Donato Cosco, Alessandra Bulotta, Monica Ventura et al. · Cancer Chemotherapy and Pharmacology · 2009 · 72 citations

Pharmacy, Oncology, Pharmacology +16

<i>In vivo</i> anti‐myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor

Paola Neri, Pierosandro Tagliaferri, Maria Teresa Di Martino et al. · British Journal of Haematology · 2008 · 63 citations · Full text

Medicine, Oncology, Pharmacology +15

Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Chiara Lazzari, Anna Spreafico, Angela Bachi et al. · Journal of Thoracic Oncology · 2011 · 40 citations · Full text

Medicine, Oncology, Pharmacology +12